A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients.

Trial Profile

A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2011

At a glance

  • Drugs Abacavir; Antiretrovirals; Lamivudine; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2009 Investigational drugs identified as reported by ClinicalTrials.gov.
    • 12 Jun 2007 Status changed from in progress to completed.
    • 11 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top